P. Black

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.

B. Schmitz-Dräger, L. Dyrskjøt, A. Kamat, 2022, Urologic oncology.

Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer

M. Babjuk, Y. Lotan, S. Shariat, 2023, European urology open science.

Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer.

P. Black, Marie-Pier St-Laurent, Jonathan Suderman, 2023, European urology oncology.

International opinions on grading of urothelial carcinoma: A survey among European Association of Urology and International Society of Urological Pathology members

A. Masson-Lecomte, M. Babjuk, R. Sylvester, 2023, European Urology.

455: Malignant Transformation of Testicular Teratoma: A Chemoresistant Phenotype

P. Spiess, A. Kamat, C. Pettaway, 2006 .

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

W. Lowrance, I. Thompson, C. Tangen, 2023, European Urology.

A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy

Y. Lotan, C. Dinney, T. Morgan, 2016 .